Sign up USA
Proactive Investors - Run By Investors For Investors

Pre-clinical data on liver disease candidate sends Ocera Therapeutics shares higher

The data will be given in what's called a poster presentation in the Netherlands.
Pre-clinical data on liver disease candidate sends Ocera Therapeutics shares higher
The candidate showed encouraging results on non-alcoholic fatty liver disease

Shares in Ocera Therapeutics Inc (NASDAQ:OCRX) raced up almost 20% as it reported positive pre-clinical data on its candidate OCR-002 ability to deal with non-alcoholic fatty liver disease (NAFLD) .

Shares in the biotech company gained 19.33% to $1.42 each.

The data will be given in what's called a poster presentation in the Netherlands.

The study investigated the effect of OCR-002 in a rat with the disease in which animals were fed a High Fat and High Cholesterol (HFHC) diet for up to 16 weeks.

NAFLD rats treated with OCR-002 showed significant reduction in the progression of fibrosis compared to untreated NAFLD animals and OCR-002 substantially reduced the liver/body weight ratio, the hepatic lipid content, and hepatic collagen.

“We are again excited to see evidence of OCR-002’s ability to target ammonia in hyperammonemia-related indications that in turn drives clinical improvement,” said Stan Bukofzer, Ocera’s chief medical officer.

Giles_55af4ddca6481.jpg


Register here to be notified of future OCRX Company articles
View full OCRX profile View Profile

Ocera Therapeutics Inc Timeline

Related Articles

ventripoint_device.png
Wed
The device can give accurate and rapid volumetric information about all four chambers of the heart
test tubes in a laboratory
March 22 2017
It’s hived off its skin division, bolstered its board and has already won new business contracts worth €5.7mln so far this year
pregnant woman sitting in park
June 13 2017
The £225,000 order is from HuanZhong Biotech, Concepta’s partner in China
Copyright © Proactiveinvestors.com, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use